Cadila Healthcare Ltd — FY25 Financial Performance & Strategic Moves

Revenue & Profit Growth Revenue from operations rose by about 31% year-on-year to ₹2,193.3 crore (versus ~₹1,676.8 crore in FY24). Profit after tax increased around 66%, coming in at ~₹540 crore compared to ~₹326 crore in the previous year. Margin Expansion & EBITDA EBITDA grew by ~82% to ~₹629.3 crore, up from ~₹346 crore. The EBITDA margin expanded significantly, to ~28.7% from ~20.6% in FY24. Margin expansion was aided by cost optimization, shifting from partner-run models to self-managed ones, and better integration of acquired businesses. Balance Sheet & Cash Position The company invested over ₹1,000 crore during FY25 on acquisitions (including businesses like iDATA, Citizenship Invest, Aadifidelis), funding most of this from internal accrual. As of 31 March 2025, Cadila had a net cash position of about ₹928 crore, highlighting a strong liquidity posture. Strategic Moves & Investments Cadila has expanded through acquisitions, which has helped in broadening its business mix beyond just its traditional pharma segments. It has also divested its animal health business in India and some other countries, using proceeds to reduce debt and channel resources toward innovation, biosimilars, vaccines, and higher-value future growth areas. Outlook & Challenges The company is likely to focus more on longer gestation “new growth areas” like biosimilars, vaccines and specialty pharma. Maintaining margin gains may depend on managing cost of goods, R&D spending and integrating acquired firms. Also relevant will be regulatory approvals, global demand in key markets, and how well the new businesses scale.